Abstract
Cognitive decline is a common feature of Parkinson’s disease, and many of these cognitive deficits fail to respond to dopaminergic therapy. Therefore, targeting other neuromodulatory systems represents an important therapeutic strategy. Among these, the locus coeruleus-noradrenaline system has been extensively implicated in response inhibition deficits. Restoring noradrenaline levels using the noradrenergic reuptake inhibitor atomoxetine can improve response inhibition in some patients with Parkinson’s disease, but there is considerable heterogeneity in treatment response. Accurately predicting the patients who would benefit from therapies targeting this neurotransmitter system remains a critical goal, in order to design the necessary clinical trials with stratified patient selection to establish the therapeutic potential of atomoxetine. Here, we test the hypothesis that integrity of the noradrenergic locus coeruleus explains the variation in improvement of response inhibition following atomoxetine. In a double-blind placebo-controlled randomised crossover design, 19 people with Parkinson’s disease completed an acute psychopharmacological challenge with 40 mg of oral atomoxetine or placebo. A stop-signal task was used to measure response inhibition, with stop-signal reaction times obtained through hierarchical Bayesian estimation of an ex-Gaussian race model. Twenty-six control subjects completed the same task without undergoing the drug manipulation. In a separate session, patients and controls underwent ultra-high field 7T imaging of the locus coeruleus using a neuromelanin-sensitive magnetisation transfer sequence. The principal result was that atomoxetine improved stop-signal reaction times in those patients with lower locus coeruleus integrity. This was in the context of a general impairment in response inhibition, as patients on placebo had longer stop-signal reaction times compared to controls. We also found that the caudal portion of the locus coeruleus showed the largest neuromelanin signal decrease in the patients compared to controls. Our results highlight a link between the integrity of the noradrenergic locus coeruleus and response inhibition in Parkinson’s disease patients. Furthermore, they demonstrate the importance of baseline noradrenergic state in determining the response to atomoxetine. We suggest that locus coeruleus neuromelanin imaging offers a marker of noradrenergic capacity that could be used to stratify patients in trials of noradrenergic therapy and to ultimately inform personalised treatment approaches.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Registered on ISRCTN registry with study ID ISRCTN46299660 (https://doi.org/10.1186/ISRCTN46299660) The study was retrospectively registered because it was exempt from Clinical Trials status by the UK Medicines and Healthcare Products Regulatory Authority (MHRA). However, we have endeavoured to retrospectively register it in order to meet compliance requirements for preprint and journal submissions.
Funding Statement
This study was supported by Parkinson's UK (grant number K-1702) and the Cambridge Centre for Parkinson-plus. CO was supported by a Neil Hamilton Fairley Fellowship from the Australian National Health and Medical Research Council (GNT1091310). FHH was supported by a Cambridge Trust Vice-Chancellor's Award and Fitzwilliam College Scholarship. NH was supported by the Association of British Neurologists - Patrick Berthoud Charitable Trust (RG99368). KAT was supported by supported by the British Academy (PF160048) and the Guarantors of Brain (101149). CHWG is supported by a RCUK/UKRI Research Innovation Fellowship awarded by the Medical Research Council (MR/R007446/1). JBR was supported by a UK Medical Research Council Intramural Programme Grant (SUAG/051 G101400) and Research Grant (MR/P01271X/1), a James S. McDonnell Foundation 21st Century Science Initiative Scholar Award in Understanding Human Cognition, and the Wellcome Trust (103838). This study was carried out at/supported by the NIHR Cambridge Clinical Research Facility and the NIHR Cambridge Biomedical Research Centre Dementia and Neurodegeneration Theme (ref. 146281). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
East of England - Cambridge Central Research Ethics Committee (REC 10/H0308/34)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code and data to reproduce manuscript figures, statistical analyses and stop-signal task modelling is freely available through the Open Science Framework [OSF link to be added].
